Vascular Manifestations of COVID-19 – Thromboembolism and Microvascular Dysfunction
Open Access
- 26 October 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 7, 598400
- https://doi.org/10.3389/fcvm.2020.598400
Abstract
The coronavirus pandemic has reportedly infected over 31.5 million individuals and caused over 970,000 deaths worldwide (as of 22nd Sept 2020). This novel coronavirus, officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), although primarily causes significant respiratory distress, can have significant deleterious effects on the cardiovascular system. Severe cases of the virus frequently result in respiratory distress requiring mechanical ventilation, often seen, but not confined to, individuals with pre-existing hypertension and cardiovascular disease, potentially due to the fact that the virus can enter the circulation via the lung alveoli. Here the virus can directly infect vascular tissues, via TMPRSS2 spike glycoprotein priming, thereby facilitating ACE-2-mediated viral entry. Clinical manifestations, such as vasculitis, have been detected in a number of vascular beds (e.g., lungs, heart, and kidneys), with thromboembolism being observed in patients suffering from severe coronavirus disease (COVID-19), suggesting the virus perturbs the vasculature, leading to vascular dysfunction. Activation of endothelial cells via the immune-mediated inflammatory response and viral infection of either endothelial cells or cells involved in endothelial homeostasis, are some of the multifaceted mechanisms potentially involved in the pathogenesis of vascular dysfunction within COVID-19 patients. In this review, we examine the evidence of vascular manifestations of SARS-CoV-2, the potential mechanism(s) of entry into vascular tissue and the contribution of endothelial cell dysfunction and cellular crosstalk in this vascular tropism of SARS-CoV-2. Moreover, we discuss the current evidence on hypercoagulability and how it relates to increased microvascular thromboembolic complications in COVID-19.Keywords
This publication has 136 references indexed in Scilit:
- Cross-talk between the complement and the kinin system in vascular permeabilityImmunology Letters, 2011
- Endothelial Cells Are Central Orchestrators of Cytokine Amplification during Influenza Virus InfectionCell, 2011
- Endothelium—role in regulation of coagulation and inflammationSeminars in Immunopathology, 2011
- Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasisBlood, 2010
- The NLRP3 Inflammasome Mediates In Vivo Innate Immunity to Influenza A Virus through Recognition of Viral RNAImmunity, 2009
- Oxidative Stress, Nitric Oxide Synthase, and Superoxide DismutaseHypertension, 2008
- Evolving functions of endothelial cells in inflammationNature Reviews Immunology, 2007
- Delay of acute intracellular pH recovery after acidosis decreases endothelial cell activationJournal of Cellular Physiology, 2006
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery.JCI Insight, 1986